Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Effective Results with a Specialized Immunotherapy for Recurrent and Metastatic Cervical Cancer

Effective Results with a Specialized Immunotherapy for Recurrent and Metastatic Cervical Cancer

Recurrent, metastatic (stage 4) or treatment-resistant cervical cancer creates a serious unmet need for effective treatments, because most patients are young and survival rates at this stage of cervical cancer are low. Adoptive cell transfer using tumor-infiltrating lymphocytes (TILs) has shown substantial, durable responses in some patients with recurrent cervical cancer. Data from the phase 2 clinical study investigating this treatment, innovaTIL-04, were presented by Jazaeri and colleagues at the 2019 ASCO Congress.

Design of the innovaTIL-04 Study

This ongoing, open-label, multicenter clinical trial in patients with cervical cancer who previously received at least one line of chemotherapy evaluates LN-145 TIL treatment’s safety and efficacy. Patients in this study must not have previously received immune checkpoint inhibitor immunotherapy.

The study’s primary endpoint was objective response rate. Secondary endpoints include response duration, disease control rate and safety. Tumors collected surgically at patients’ hospitals were sent to a TIL production facility for a 22-day manufacturing process. The final cellular immunotherapy product, LN-145 TIL , is frozen and sent to the patients’ treatment centers. Patients received lymphodepletion with cyclophosphamide and fludarabine chemotherapy 1 week before cellular immunotherapy to mildly suppress bone marrow and make room for new T lymphocytes. The main immunotherapy consisted of a single LN-145 TIL cellular immunotherapy infusion, followed by 6 doses of interleukin-2 (IL-2).

As of February 2019, 27 patients had received 2nd-generation TIL treatment; their mean age was 47 and they had received an average of 2.6 previous treatment lines.

Results

  • As of May 14, 2019, 27 patients showed an objective response rate of 44% (3 complete and 9 partial responses), and the cancer control rate was 85%.
  • At an average follow-up of 7.4 months, 10 patients continued to respond to treatment and the median disease control rate had not yet been reached.
  • Most side effects were associated with advanced cancer, lymphodepletion and IL-2 administration.

The researchers "LN-145 resulted in an objective response rate of 44% with an acceptable safety and efficacy profile in patients with previously treated cervical cancer. LN-145 offers patients a feasible treatment option that warrants further investigation." said.

Commentary

This cellular immunotherapy study presented at ASCO 2019 represents an exciting new technology with promise for treating cervical cancer and possibly other solid (organ) tumors. Tumor-infiltrating lymphocytes (TILs) are found in many tumor types and are probably associated with favorable disease outcomes, because they may indicate hot or immunotherapy-responsive inflamed tumors. For patients with TILs in the tumor microenvironment , collecting, expanding and returning TILs to the patient, as was done here, appears to be an effective strategy for overcoming the immune system’s blindness to cancer.

*

The types of immunotherapy used in cancer can be seen below:

cancer immunotherapy types cellular immunotherapy

Sources

Amir A. Jazaeri, Emese Zsiros, Rodabe Navroze Amaria ve ark.
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
ASCO 2019 Presented Saturday, June 1, 2019

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Effective Results with a Specialized Immunotherapy for Recurrent and Metastatic Cervical Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy